Quote & Headlines
Market Currents
StockTalk
Today
5d
1m
3m
1y
5y
10y
52wk high:
52wk low:
EPS:
PE:
Div Rate:
Yield:
Market Cap:
Volume:
1,364 people get ELN articles and Market Currents by email alert.
Get email alerts on ELN »
HEADLINES:
ALL
|
PRO
|
FOCUS
|
RELATED
|
TRANSCRIPTS
|
NEWS & PR
-
-
Business Wire (Wed, 5:14PM)
-
-
-
-
Business Wire (Mon, 2:03AM)
-
Business Wire (Mon, 2:02AM)
-
Business Wire (Apr 25, 2013)
-
Business Wire (Apr 24, 2013)
-
-
Business Wire (Apr 22, 2013)
-
Business Wire (Apr 18, 2013)
-
-
Business Wire (Apr 15, 2013)
-
-
Business Wire (Apr 12, 2013)
-
Business Wire (Apr 10, 2013)
-
Business Wire (Apr 3, 2013)
-
Business Wire (Apr 2, 2013)
-
-
-
-
-
-
Elan Call Buyers Look for Springtime RallyoptionMONSTER • Wed, Apr 6, 2011 -
-
Elan Agrees to Pay $203.5M in Off-Label Marketing CasePharmalot • Thu, Dec 16, 2010 -
Elan, Dissident Directors Reach DetentePharmalot • Fri, Sep 17, 2010
-
-
-
Elan Renews Spin-Off HopesThe Burrill Report • Sun, Apr 25, 2010
-
-
A Bull's on the Loose at ElanMike Huckman • Thu, Jan 8, 2009
-
-
-
Elan Corp. Now Dirt CheapNotable Calls • Fri, Aug 1, 2008 -
-
-
Elan: New Multiple Sclerosis Drug Sales Will Be KeyMichael Shulman • Mon, Dec 3, 2007
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Pharma Continues To Move Forward With Alzheimer's TherapiesVineet Dutta • Wed, Dec 19, 2012 -
VIX - Options Volatility Sonar: Tuesday RecapErick McKitterick • Tue, Dec 11, 2012
-
-
-
Elan Management Discusses Q2 2012 Results - Earnings Call TranscriptWed, Jul 25, 2012
-
Elan Q4 2009 Earnings Call TranscriptWed, Feb 10, 2010
-
Elan Q3 2007 Earnings Call TranscriptThu, Oct 25, 2007 • 1 Comment
-
Elan Q2 2007 Earnings Call TranscriptFri, Jul 27, 2007
-
Business Wire (Wed, 5:14PM)
-
Business Wire (Mon, 2:03AM)
-
Business Wire (Mon, 2:02AM)
-
Business Wire (Apr 25, 2013)
-
Business Wire (Apr 24, 2013)
-
at CNBC.com (Apr 22, 2013)
-
Business Wire (Apr 22, 2013)
-
Business Wire (Apr 18, 2013)
-
at CNBC.com (Apr 16, 2013)
-
at CNBC.com (Apr 16, 2013)
-
Business Wire (Apr 15, 2013)
-
at CNBC.com (Apr 15, 2013)
-
at CNBC.com (Apr 15, 2013)
-
at CNBC.com (Apr 12, 2013)
-
Business Wire (Apr 12, 2013)
-
Business Wire (Apr 10, 2013)
-
Business Wire (Apr 3, 2013)
-
Business Wire (Apr 2, 2013)
-
Business Wire (Apr 2, 2013)
ELN vs. ETF Alternatives
Company Description
Elan Corporation, plc, an Irish public limited company, is a neuroscience-based biotechnology company, listed on the Irish and New York Stock Exchanges, and headquartered in Dublin, Ireland. We were incorporated as a private limited company in Ireland in December 1969 and became a public limited... More
- All
- | Earnings
- | Dividends
- | M&A
- | On the move
- Wednesday, May 15, 11:50 AM Seth Klarman added two new positions to Baupost in Q1, with Elan (ELN) now 3.5% of his portfolio and DirecTV (DTV) 0.38%. He added to already major positions in BP, AIG, ROVI, and IDIX, and completely sold out of GNW, and ANV. 1 Comment
- Monday, May 13, 5:49 AM Elan (ELN) will make a one time cash payment of $1B to Theravance (THRX) for a 21% participation interest in future royalty payments from THRX's four respiratory collaborations with GlaxoSmithKline (GSK) including the recently-approved Breo Ellipta/Relvar treatment for COPD. The news comes on the heels of THRX's earnings report and concurrent announcement that it will split into two separate publicly traded companies. (PR) Comment! [Healthcare]
- Thursday, May 2, 7:25 AM Royalty Pharma officially submits its $11.25/share cash offer to Elan (ELN), again making the case that this month's Dutch Auction makes clear the price is a fair one. "J&J's actions (they tendered at $11.25) speak volumes." (PR) 1 Comment [Healthcare, Breaking News, M&A]
- Wednesday, April 24, 5:35 AM Elan (ELN) Q1 EPS of -$0.05. Revenue including Tysabri of $344.0M (+19% Y/Y). (PR) Comment! [Earnings, Breaking News, Healthcare]
- Wednesday, April 24, 12:05 AM Notable earnings before Wednesday’s open: ABB, ABX, ASH, ATI, AVY, BA, BYD, CFR, CKSW, COR, CP, CS, CVE, DPS, EDU, ELN, EMN, ERIC, F, FDML, GD, GLW, GRA, HCBK, HES, ICON, LAD, LL, LLY, LO, MDCO, MSI, MTH, NDAQ, NOC, NS, NVS, NYCB, OC, OCR, OSIS, PG, PLD, PX, RES, ROK, S, SO, SVU, TEL, TKR, TMO, TROW, TUP, USG, VLY, VMED, WAB, WHR, WLP, WM, WYN Comment! [Earnings]
- Tuesday, April 23, 5:30 PM Notable earnings before Wednesday’s open: ABB, ABX, ASH, ATI, AVY, BA, BYD, CFR, CKSW, COR, CP, CS, CVE, DPS, EDU, ELN, EMN, ERIC, F, FDML, GD, GLW, GRA, HCBK, HES, ICON, LAD, LL, LLY, LO, MDCO, MSI, MTH, NDAQ, NOC, NS, NVS, NYCB, OC, OCR, OSIS, PG, PLD, PX, RES, ROK, S, SO, SVU, TEL, TKR, TMO, TROW, TUP, USG, VLY, VMED, WAB, WHR, WLP, WM, WYN Comment! [Earnings]
- Monday, April 22, 6:46 AM Elan (ELN) has rebuffed Royalty Pharma's reduced $11.25-a-share takeover offer, saying the bid "grossly undervalues" the Irish pharmaceuticals company. Royalty cut its bid last week from $12 following a $1B stock buyback by Elan, the results of which suggest that the company's investors support the view that Royalty's bid is too low - 73% of shares excluding those of Johnson & Johnson were not tendered in the pre-announced price range of $11.25-$13.00. (PR) 1 Comment [Healthcare, M&A]
- Thursday, April 18, 9:40 AM Johnson & Johnson (JNJ) tenders 107.4M Elan (ELN) shares at the strike price of $11.25 in the latter's $1B stock buyback. The total number of shares tendered is 239.7M, of which Elan plans to purchase 76%. Elan is retiring 14.8% of the stock in issue as part of the repurchase plan. (PR) Comment! [Healthcare]
- Monday, April 15, 7:29 AM U.S. investment firm Royalty Pharma offers to acquire Elan (ELN) for $11-12/share, depending on the outcome of its dutch auction. Royalty says its analysis of Elan's Tysabri royalty and the implied valuation of Elan's economics in Tysabri leads its to believe its offer "represents a full and fair value for Elan." Ireland's Takeover Panel had given Royalty until May 10 to announce a takeover offer or end its $6.5B pursuit of the drugmaker. Elan has rejected previous overtures. (PR) Comment! [Breaking News, Healthcare, M&A]
- Friday, April 12, 4:48 PM SAC Capital is reportedly being sued by Wyeth investors over insider trading, just one month after it settled with federal regulators for over $600M under similar allegations. SAC came under fire last year as former fund manager Mathew Martoma was charged with illegally obtaining results from an Alzheimer's drug trial being conducted by Wyeth (now part of Pfizer (PFE)) and Elan (ELN), then trading on the information before the data was made public. Comment! [Financials, Healthcare]
- Friday, April 12, 10:59 AM Elan's (ELN -1.3%) shareholders have overwhelmingly approved a plan to buy back $1B in stock following the sale of Tsabri to Biogen Idec (BIIB +2.4%), as speculation mounts that an earlier takeover indication by Royalty Pharma might be sweetened. Royalty approached ELN in February with an $11 per share potential offer, valuing the company at $6.55B, which was rejected by ELN. Last week, Ireland's Takeover Panel told the pharmaceutical investor to either step up and announce an official takeover offer for the company by May 10, or walk away. Comment! [Healthcare, Global & FX, M&A]
- Wednesday, April 3, 8:01 AM Ireland's Takeover Panel tells U.S. investment firm Royalty Pharma to either announce a takeover offer for Elan (ELN +0.1%) by May 10 or end its $6.5B pursuit of the drugmaker. Elan, which has rejected Royalty's indicative approach of $11/share, welcomed the panel's deadline. (PR) Comment! [Healthcare, M&A]
- Tuesday, April 2, 6:08 PM Biogen Idec (BIIB) completes its purchase of Elan's (ELN) interest in Tysabri, gaining full strategic, commercial and decision-making rights to the relapsing MS drug treatment. [BIIB plans to give further details and updated financial guidance during it's upcoming Q1 earnings announcement. Shares +0.3% AH. Comment! [Healthcare, M&A]
- Monday, March 18, 8:10 AM Biogen's (BIIB) and Elan's (ELN) Tysabri treatment has demonstrated its "efficacy compared to other multiple sclerosis (MS) treatments" in several studies. The research also provided more data that shows the stability of anti-JC virus (JCV) antibodies, and improved outcomes for the brain infection PML if it's detected early. (PR) 1 Comment [Healthcare]
- Monday, March 11, 9:29 AM Elan (ELN) +4.2% premarket after announcing Friday it will pay as much as $13/share, or a premium of 13% from Friday’s closing price, to buy back stock in a plan intended to reward stockholders who remain invested in the company following the sale of its Tysabri multiple sclerosis drug. 1 Comment [Healthcare, On the Move]
-
Friday, March 8, 5:37 PM
After-hours top gainers, as of 5:15 p.m.: ELN +7%. THOR +3%. GAME +3%. TTI +2%. VELT +2%.
After-hours top losers: RMBS -4%. LKQ -4%. EZPW -4%. MBLX -3%. CYS -3%. Comment! [On the Move]
Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.